home > news > 2012 > august > simcyp releases version 12 of population-based simulator
Simcyp releases Version 12 of Population-based Simulator
Date: 01 Aug 2012
Simcyp is pleased to announce the release of Version 12 of its Population-based Simulator, the pharmaceutical industry’s most sophisticated platform for the quantitative prediction of drug-drug interactions and pharmacokinetic-pharmacodynamic outcomes in both healthy subjects and diverse patient populations.
Version 12 extends Simcyp’s lead in its recognised field of expertise with the implementation of a mechanistic kidney model, expanded drug distribution models, and enhancements and additions to its extensive compound libraries and paediatric module. Also, the incorporation of physiologically-based pharmacokinetic (PBPK) models for therapeutic proteins propagates the utility of the Simcyp Simulator into the development of biologics.
Simcyp’s focus on cutting-edge research sets the standard amongst modelling and simulation providers. In this respect, the Simcyp approach continues to be enhanced by the commission of academic research projects to fill knowledge gaps impeding progress in the application of PBPK modelling, such as those related to transporter abundances and associated scaling factors.
Commenting on the release, Professor Amin Rostami, VP Research and Development, Simcyp, said: “Recent publications1 and industry guidelines from the European Medicines Agency and US FDA highlight the trend towards acceptance of more mechanistic approaches to modelling. The Simcyp team takes pride in their contribution to the field and promoting the use of quantitative approaches via its enabling tools. We continue to consolidate our core strengths whilst pushing the boundaries of PBPK-PD modelling. The latest release is a practical manifestation of this commitment.”
Professor Geoff Tucker, VP Translational Science at Certara and Head of Simcyp Consultancy, commented: “The Simcyp Consortium has ensured both rapid and focused development of the Simcyp Simulator, and we believe that this model continues to provide significant scientific, regulatory and financial benefit to our members. R&D on Version 13 is underway and the current consultation process on Version 14 is poised to exploit the further potential of PBPK-PD modelling as an indispensable tool in modern drug discovery and development.”
Version 12 of the Simcyp Simulator is now available to all Consortium Members and academic associates with current not-for-profit license agreements.